PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6527529

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CELGENE INTERNATIONAL II SÀRL	06/22/2020

RECEIVING PARTY DATA

Name:	RECEPTOS LLC
Street Address:	430 EAST 29TH STREET, 14TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10016

PROPERTY NUMBERS Total: 127

Property Type	Number
Patent Number:	8362048
Patent Number:	9388147
Patent Number:	10239846
Patent Number:	9394264
Patent Number:	8357706
Patent Number:	8507538
Patent Number:	9481659
Patent Number:	8816121
Patent Number:	8501982
Patent Number:	9278910
Patent Number:	9700543
Patent Number:	9187522
Patent Number:	8778923
Patent Number:	10259823
Patent Number:	9260427
Patent Number:	9598430
Patent Number:	9474755
Patent Number:	9839664
Patent Number:	9795613
Patent Number:	10034886

PATENT REEL: 055192 FRAME: 0805

506480753

Property Type	Number
Application Number:	61485872
Application Number:	61618424
Application Number:	13470104
Application Number:	61261301
Application Number:	61262474
Application Number:	15170686
Application Number:	13740661
Application Number:	16270469
Application Number:	16552960
Application Number:	13740669
Application Number:	61261282
Application Number:	61261295
Application Number:	14563742
Application Number:	13941695
Application Number:	14975244
Application Number:	61486184
Application Number:	61353174
Application Number:	14626719
Application Number:	14329393
Application Number:	14873563
Application Number:	61491446
Application Number:	61535750
Application Number:	61569759
Application Number:	15608740
Application Number:	15050315
Application Number:	61734300
Application Number:	61569754
Application Number:	61570789
Application Number:	14878660
Application Number:	61981643
Application Number:	61833737
Application Number:	61836950
Application Number:	61898971
Application Number:	15033311
Application Number:	15982909
Application Number:	62090040
Application Number:	62161650
Application Number:	62028962

Property Type	Number
Application Number:	16827515
Application Number:	15804762
Application Number:	16538505
Application Number:	16218278
Application Number:	16538553
Application Number:	16008773
Application Number:	16835046
Application Number:	16227510
Application Number:	62090268
Application Number:	62161658
Application Number:	62164113
Application Number:	15693274
Application Number:	62293731
Application Number:	62293728
Application Number:	62478496
Application Number:	62383202
Application Number:	16335641
Application Number:	16337298
Application Number:	62402565
Application Number:	16337292
Application Number:	62401762
Application Number:	16608134
Application Number:	62491892
Application Number:	16611451
Application Number:	62502909
Application Number:	62504206
Application Number:	62544467
Application Number:	62648858
Application Number:	62826769
Application Number:	62826778
Application Number:	62648875
Application Number:	62826790
Application Number:	62648878
Application Number:	62648889
Application Number:	62826794
Application Number:	62826797
Application Number:	62648894
Application Number:	62654152

Property Type	Number
Application Number:	62662102
Application Number:	62648837
Application Number:	62839495
Application Number:	62690197
Application Number:	63018327
Application Number:	63001073
Application Number:	63018333
Application Number:	63001085
Application Number:	63018347
Application Number:	63001090
PCT Number:	US2012037622
PCT Number:	US2010056760
PCT Number:	US2010056757
PCT Number:	US2010056759
PCT Number:	US2012037609
PCT Number:	US2011039873
PCT Number:	US2012040250
PCT Number:	US2012069289
PCT Number:	US2014041997
PCT Number:	US2014063504
PCT Number:	US2015042114
PCT Number:	US2015065109
PCT Number:	US2017049768
PCT Number:	US2017054298
PCT Number:	US2017054053
PCT Number:	US2018029597
PCT Number:	US2018031695
PCT Number:	US2020025132
PCT Number:	US2020025138
PCT Number:	US2020025141
PCT Number:	US2020025142

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 206-622-4900
Email: chrisr@seedip.com
Correspondent Name: KARL R. HERMANNS
Address Line 1: SEED IP LAW GROUP LLP

PATENT

REEL: 055192 FRAME: 0808

Address Line 2: 701 FIFTH AVENUE, SUITE 5400
Address Line 4: SEATTLE, WASHINGTON 98104

ATTORNEY DOCKET NUMBER:	800059.006
NAME OF SUBMITTER:	KARL R. HERMANNS
SIGNATURE:	/Karl R. Hermanns/
DATE SIGNED:	02/01/2021

Total Attachments: 42

source=Celgene to Receptos Assignment#page1.tif source=Celgene to Receptos Assignment#page2.tif source=Celgene to Receptos Assignment#page3.tif source=Celgene to Receptos Assignment#page4.tif source=Celgene to Receptos Assignment#page5.tif source=Celgene to Receptos Assignment#page6.tif source=Celgene to Receptos Assignment#page7.tif source=Celgene to Receptos Assignment#page8.tif source=Celgene to Receptos Assignment#page9.tif source=Celgene to Receptos Assignment#page10.tif source=Celgene to Receptos Assignment#page11.tif source=Celgene to Receptos Assignment#page12.tif source=Celgene to Receptos Assignment#page13.tif source=Celgene to Receptos Assignment#page14.tif source=Celgene to Receptos Assignment#page15.tif source=Celgene to Receptos Assignment#page16.tif source=Celgene to Receptos Assignment#page17.tif source=Celgene to Receptos Assignment#page18.tif source=Celgene to Receptos Assignment#page19.tif source=Celgene to Receptos Assignment#page20.tif source=Celgene to Receptos Assignment#page21.tif source=Celgene to Receptos Assignment#page22.tif source=Celgene to Receptos Assignment#page23.tif source=Celgene to Receptos Assignment#page24.tif source=Celgene to Receptos Assignment#page25.tif source=Celgene to Receptos Assignment#page26.tif source=Celgene to Receptos Assignment#page27.tif source=Celgene to Receptos Assignment#page28.tif source=Celgene to Receptos Assignment#page29.tif source=Celgene to Receptos Assignment#page30.tif source=Celgene to Receptos Assignment#page31.tif source=Celgene to Receptos Assignment#page32.tif source=Celgene to Receptos Assignment#page33.tif source=Celgene to Receptos Assignment#page34.tif source=Celgene to Receptos Assignment#page35.tif source=Celgene to Receptos Assignment#page36.tif source=Celgene to Receptos Assignment#page37.tif source=Celgene to Receptos Assignment#page38.tif source=Celgene to Receptos Assignment#page39.tif

source=Celgene to Receptos Assignment#page40.tif source=Celgene to Receptos Assignment#page41.tif source=Celgene to Receptos Assignment#page42.tif

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), effective as of June 22, 2020 (the "Effective Date"), is made by and between Receptos LLC a limited liability company formed under the laws of Delaware ("Assignee") and Celgene International II Sarl, a company organized under the laws of Switzerland ("Assignor"). Assignee and Assignor are sometimes herein each referred to as a "Party" and collectively as the "Parties." Capitalized terms used herein but not otherwise defined herein shall have the meanings set forth in the Assignment Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Assignment Agreement, dated as of June 22, 2020 (as may be amended or restated from time to time, the "Assignment Agreement"), pursuant to which, among other things, Assignor agreed to assign, transfer and deliver to Assignee certain Transferred IP (as defined in the Assignment Agreement), as more fully described in the Assignment Agreement, on the terms and subject to the conditions set forth in the Assignment Agreement;

WHEREAS, the Transferred IP includes, without limitation, the patents and patent applications set forth on <u>Annex A</u> hereto (collectively, the "*Transferred Patents*"); and

WHEREAS, Assignor and Assignee now desire to enter into this Assignment to evidence the assignment, transfer and delivery to Assignee of the Transferred Patents;

NOW THEREFORE, for good and valuable consideration, including the past consideration set forth in the Assignment Agreement, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

- Assignment. Assignor hereby assigns, transfers and delivers to Assignee, and Assignee hereby acquires from Assignor, all rights and interests of Assignor in and to the Transferred Patents, for the United States and for all foreign countries (including, without limitation, all rights therein provided by international conventions and treaties), including, without limitation, any reissues, divisions, continuations, continuations-in-part, extensions, reexaminations and foreign equivalents thereof, all inventions disclosed therein and improvements thereto, all rights to claim priority thereto or therefrom, and all rights therein provided by international treaties and conventions, together with all associated income, royalties, damages or payments accrued, due or payable as of the Effective Date or thereafter and including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Transferred Patents, with the right to sue for, and collect the same, in each case, for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.
- 2. <u>No Warranties</u>. Except as expressly provided in the Assignment Agreement, Assignor makes no warranties, express or implied, with respect to the Transferred Patents.

- 3. <u>Recordal</u>. Assignor hereby authorizes and requests the Commissioner of Patents of the United States, and any other official of any applicable Governmental Authority, to record this Assignment and to issue any and all registrations from any and all applications for registration included in the Transferred Patents to and in the name of Assignee.
- 4. <u>Further Assurances</u>. Assignor shall, at the cost and expense of Assignee, timely execute and deliver any additional documents and perform such additional acts necessary or desirable to record and perfect the interest of Assignee in and to the Transferred Patents.
- 5. <u>Interpretation</u>. This Assignment is intended to implement the provisions of the Assignment Agreement, is expressly subject to the terms and conditions thereof, and shall not be construed to enhance, extend or limit the representations and warranties, rights, obligations or remedies of any party thereunder. In case of any conflict or inconsistency between the terms and conditions of this Assignment and the terms and conditions of the Assignment Agreement, the terms and conditions of the Assignment Agreement shall govern.
- 6. <u>Amendment</u>. Except as otherwise provided herein, no amendment, modification or supplement of any provision of this Assignment shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.
- 7. <u>Waiver</u>. No provision of this Assignment shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.
- 8. <u>Counterparts, Facsimile Signatures</u>. This Assignment may be executed in two (2) or more counterparts and such counterparts taken together shall constitute one and the same agreement. This Assignment may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures.
- 9. <u>Descriptive Headings</u>. The descriptive headings of this Assignment are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Assignment.
- 10. Governing Law. This Assignment shall be governed and construed in accordance with the laws of the State of New York, without giving effect to any choice of law provisions thereof that would result in the application of the law of any jurisdiction other than New York. Each Party hereby submits itself for the purpose of this Assignment and any controversy arising hereunder to the exclusive jurisdiction of the state and federal courts located in the State of New York, and any courts of appeal therefrom, and waives any objection on the grounds of lack of jurisdiction (including, without limitation, venue) to the exercise of such jurisdiction over it by any such courts.
- 11. <u>Severability</u>. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable

provisions that it can be reasonably assumed that the Parties would have entered into this Assignment with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable provisions of this Assignment shall not affect the validity of this Assignment as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Assignment that it is to be reasonably assumed that the Parties would not have entered into this Assignment without the invalid, illegal or unenforceable provisions.

- 12. <u>Independent Contractors</u>. The relationship between the Parties created by this Assignment is one of independent contractors and no Party shall have the power or authority to bind or obligate the others except as expressly set forth in this Assignment.
- 13. <u>Expenses</u>. Unless otherwise provided herein, all costs and expenses incurred in connection with this Assignment and the transactions contemplated hereby shall be paid by the Party which shall have incurred the same and the other Party shall have no liability relating thereto.
- 14. <u>Third Party Beneficiaries</u>. No person or entity other than the Parties hereto and their respective Affiliates, successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Assignment.
- 15. <u>No Strict Construction</u>. This Assignment has been prepared jointly and shall not be strictly construed against any Party.

[Signature Page Immediately Follows.]

3

IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Assignment as of the Effective Date.

Title: Director

By:	
•	David Walter Pignolet
	Managing Officer
Ву:	MARIN
Name:	Sze Shean Teo Burgat
Title:	Managing Officer
	PTOS LLC osp Ltd., its sole member
By:	Kevin Mello

CELGE<u>NE INTERN</u>ATIONAL II SÀRL

IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Assignment as of the Effective Date.

CRICENE	INTERNATIONAL	RELADE
6 878 688 1487		11 3 A K 1

By: Name: Title:	Managing Officer
By:	
Name: Fitle:	Managing Officer

RECEPTOS LLC

By Crosp Ltd., its sole member

Name: Kevin Mello'
Title: Director

REEL: 055192 FRAME: 0815

Annex A

Transferred Patents

PATENTS - Joint Ownership between CIS II and The Scripps Research Institute ("TSRI")

Title Application No. Filing Path, No., Date (Patent No.) Phb, No., Path, No., Phb, Date (Patent No.) Country (Issue Date) Country (Issue Date) Status Ownership Novel Fusion Partners for the Purpose of Cystallizing G-Protein Coupled Receptors 61/618424 3/30/2012 US Lapsed Joint between CIS Purpose of Cystallizing G-Protein Coupled Receptors Permose of Cystallizing G-Protein 61/618424 3/30/2012 WO 11/22/2012 PCT Converted Joint between CIS Joint Detween CIS Purpose of Cystallizing G-Protein Coupled Receptors Permose of Cystallizing G-Protein 13/470104 5/11/2012 2012-0288913 11/15/2012 PCT Converted Joint between CIS Purpose of Cystallizing G-Protein Coupled Receptors Partners for the Purpose of Cystallizing G-Protein 2012256101 5/11/2012 2012-0288913 11/15/2012 US Pending Joint between CIS Jin and TSRI Coupled Receptors Avovel Fusion Partners for the Purpose of Cystallizing G-Protein 2012256101 5/11/2012 AU Pending Joint between CIS Jin and TSRI Coupled Receptors Novel Fusion Partners for the Purpose of Cystallizing G-Protein EP12786737.2 5/11/2012 EPO Pending								
rotein 61/485872 5/13/2011 US Lapsed votein 61/618424 3/30/2012 WO 11/22/2012 PCT Converted votein PCT/US2012/37622 5/11/2012 WO 111/22/2012 PCT Converted votein 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending votein 201391514 5/11/2012 AU Pending rotein 201391514 5/11/2012 Eurasian Pending rotein EP12786737.2 5/11/2012 EPO Pending votein 228790 5/11/2012 EPO Pending votein 617631 5/11/2012 NZ Pending votein 617631 5/11/2012 103874711 A CN Pending	Title	Application No.	Filing Date	Pub. No. (Patent No.)	Pub. Date (Issue Date)	Country	Status	Ownership
1 61/618424 3/30/2012 US Lapsed PCT/US2012/37622 5/11/2012 WO	Novel Fusion Partners for the	61/485872	5/13/2011			SU	Lapsed	Joint between CIS
61/618424 3/30/2012 US Lapsed PCT/US2012/37622 5/11/2012 WO 2012/158355 11/22/2012 PCT Converted 2012/158355 2012/2012 US Pending 2012/256101 5/11/2012 2012-0288913 11/15/2012 US Pending 201391514 5/11/2012 Eurasian Pending Org. EP12786737.2 5/11/2012 EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 US Pending EPO Pending 2012800229077 5/11/2012 I03874711 A CN Pending Pending 2012800229077 5/11/2012 I03874711 A CN Pending	Purpose of Crystallizing G- Protein							II and TSRI
	Coupled Receptors							
PCT/US2012/37622 5/11/2012 WO 11/22/2012 PCT Converted 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending 2012256101 5/11/2012 2012-0288913 11/15/2012 AU Pending 1 201391514 5/11/2012 Eurasian Pending Patent Org. Pending 1 EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 IL Pending 228790 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Novel Fusion Partners for the	61/618424	3/30/2012			$\overline{\mathrm{US}}$	Lapsed	Joint between CIS
PCT/US2012/37622 5/11/2012 WO 11/22/2012 PCT Converted 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending 2012256101 5/11/2012 AU Pending 201391514 5/11/2012 Eurasian Pending Patent Org. EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 EPO Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G-Protein							II and TSRI
PCT/US2012/37622 5/11/2012 WO 2012/158555 11/22/2012 PCT Converted 2012/158555 1 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending Pending Patent Org. 2 201391514 5/11/2012 Eurasian Pending Patent Org. 1 EP12786737.2 5/11/2012 EPO Pending P	Coupled Receptors							
2012/158555 1 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending 2012256101 5/11/2012 AU Pending 201391514 5/11/2012 Eurasian Pending Patient Org. EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 ID3874711 A 2012800229077 5/11/2012 ID3874711 A CN Pending	Novel Fusion Partners for the		5/11/2012	WO	11/22/2012	PCT	Converted	Joint between CIS
1 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending 2012256101 5/11/2012 AU Pending 201391514 5/11/2012 EP12786737.2 5/11/2012 EP12786737.2 5/11/2012 EP12786737.2 5/11/2012 EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 ID3874711 A CN Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G-Protein			2012/158555				II and TSRI
1 13/470104 5/11/2012 2012-0288913 11/15/2012 US Pending 2012256101 5/11/2012 AU Pending 201391514 5/11/2012 EP12786737.2 5/11/2012 EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 ID3874711 A CN Pending 2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors							
2012256101 5/11/2012 AU Pending 201391514 5/11/2012 Eurasian Pending EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 ID3874711 A 2012800229077 5/11/2012 IO3874711 A CN Pending	Novel Fusion Partners for the	13/470104	5/11/2012	2012-0288913	11/15/2012	US	Pending	Joint between CIS
2012256101 5/11/2012 AU Pending 201391514 5/11/2012 Eurasian Pending Patent Org. EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 IO3874711 A 2012800229077 5/11/2012 IO3874711 A CN Pending	Purpose of Crystallizing G- Protein							II and TSRI
2012256101 5/11/2012 AU Pending 201391514 5/11/2012 Eurasian Pending EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 ID3874711 A CN Pending 2012800229077 5/11/2012 IO3874711 A CN Pending	Coupled Receptors							
201391514 5/11/2012 Eurasian Pending Patent Org. EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Novel Fusion Partners for the	2012256101	5/11/2012			AU	Pending	Joint between CIS
201391514 5/11/2012 Eurasian Pending Patent Org. EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G-Protein							II and TSRI
201391514 5/11/2012 Eurasian Pending Patent Org. EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors							
Patent Org. EP12786737.2 5/11/2012 EP0 Pending 228790 5/11/2012 ID3874711 A CN Pending Patent Org. Patent Org. Patent Org. Pending EPO Pending EPO Pending CN Pending	Novel Fusion Partners for the	201391514	5/11/2012			Eurasian	Pending	Joint between CIS
EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G- Protein					Patent		II and TSRI
EP12786737.2 5/11/2012 EPO Pending 228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors					Org.		
228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Novel Fusion Partners for the	EP12786737.2	5/11/2012			EPO	Pending	Joint between CIS
228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G- Protein							II and TSRI
228790 5/11/2012 IL Pending 617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors							
617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Novel Fusion Partners for the	228790	5/11/2012			IL	Pending	Joint between CIS
617631 5/11/2012 NZ Pending 2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G-Protein							II and TSRI
1 2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors							
2012800229077 5/11/2012 103874711 A CN Pending	Novel Fusion Partners for the	617631	5/11/2012			NZ	Pending	Joint between CIS
2012800229077 5/11/2012 103874711 A CN Pending	Purpose of Crystallizing G- Protein							II and TSRI
2012800229077 5/11/2012 103874711 A CN Pending	Coupled Receptors							
	Novel Fusion Partners for the	2012800229077	5/11/2012	103874711 A		CN	Pending	Joint between CIS
Coupled Receptors Coupled Receptors	Purpose of Crystallizing G-Protein							II and TSRI
	Coupled Receptors							

PATENT REEL: 055192 FRAME: 0816

NAI-1512904354v2

PATENTS - Sole Ownership by CIS II

Seed No.	Country Title	Title	Status	Application No.	Filing Date	Patent No.	Issue Date Assignee	Assignee
800059.401/P1	US	Selective Sphingosine 1	NP-Filed	61/261301	11/13/2009			CIS II
		Phosphate Modulators						
		and Methods of Chiral						
		Synthesis						
800059.401/P2	US	Selective Sphingosine 1	NP-Filed	61/262474	11/18/2009			CIS II
		Phosphate Modulators						
		and Methods of Chiral						
		Synthesis						
800059.401	SU	Selective Sphingosine 1	Granted	12/946819	11/15/2010	8362048	1/29/2013	CIS II
		Phosphate Receptor						
		Modulators and Methods						
		of Chiral Synthesis						

7

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.401	CN	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201080061144.8	11/15/2010	ZL201080061144.8	7/1/2015	CIS II
800059.401/1	CN	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201510295907.X	11/15/2010	ZL201510295907.X	5/29/2018	CIS II
800059.401	СҮ	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059.401	CZ	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059.401	DE	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059.401	DK	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059.401	EA	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201290323	11/15/2010	024801	10/31/2016	CIS II
800059.401/1	EA	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Allowed	201690391	11/15/2010			CIS II
800059.401	EE	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.401	NZ	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	599915	11/15/2010	599915	10/29/2014	CIS II
800059.401	РН	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	1-2012-500939	11/15/2010	1-2012-500939	3/21/2016	CIS II
800059,401/1	PH	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	1-2015-502708	11/15/2010	1-2015-502708	3/2/2018	CIS II
800059,401	PL	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059,401	PT	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059,401	RO	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059,401	RS	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830880.0	11/15/2010	2498610	3/14/2018	CIS II
800059,401	RU	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201290323	11/15/2010	024801	10/31/2016	CIS II
800059.401/1	RU	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Allowed	201690391	11/15/2010			CIS II

800059.402/C1	800059.401	800059.401	800059.401	800059.401	800059.401	800059.401/1	800059.401	800059.401	Seed No.
US	WO	TR	SM	SK	SI	SG	SG	SE	Country
Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Title
Granted	Converted	Granted	Granted	Granted	Granted	Granted	Abandoned	Granted	Status
14/634439	US2010/056760	10830880.0	10830880.0	10830880.0	10830880.0	10201407357P	201203374-2	10830880.0	Application No.
2/27/2015	11/15/2010	11/15/2010	11/15/2010	11/15/2010	11/15/2010	11/15/2010	11/15/2010	11/15/2010	Filing Date
9394264		2498610	2498610	2498610	2498610	10201407357P		2498610	Patent No.
7/19/2016		3/14/2018	3/14/2018	3/14/2018	3/14/2018	1/19/2018		3/14/2018	Issue Date
CIS II	CIS II	CIS II	CIS II	CIS II	CIS II	CIS II	CIS II	CIS II	Assignee

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.402	LU	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	$\Gamma\Lambda$	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059,402	MC	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059,402	MK	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	MT	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	MX	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	MX/a/2012/005562	11/15/2010	323258	9/2/2014	CIS II
800059.402	MY	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	PI-2012002085	11/15/2010	MY-160907-A	3/31/2017	CIS II
800059,402	NL	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059,402	ON	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II

21

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.402	NZ	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	599913	11/15/2010	599913	12/2/2014	CIS II
800059.402	PH	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Pending	1-2012-500938	11/15/2010			CIS II
800059.402	PL	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	PT	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	RO	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	RS	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	RU	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201290331	11/15/2010	023183	5/31/2016	CIS II
800059.402	SE	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	10830877.6	11/15/2010	2498611	1/10/2018	CIS II
800059.402	SG	Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis	Granted	201203370-0	11/15/2010	180753	11/13/2014	CIS II

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.403	BE	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	BR	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Published	BR1120120114310	11/15/2010			CIS II
800059,403	CA	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	2780641	11/15/2010	2780641	5/5/2019	CIS II
800059.403	СН	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	CN	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	201080061373.X	11/15/2010	ZL201080061373.X	4/20/2016	CIS II
800059.403/1	CN	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Abandoned	201510369450.2	11/15/2010			CIS II
800059.403	DE	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	DK	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	EA	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	201290329	11/15/2010	0025672	1/30/2017	CIS II
800059.403	EP	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Converted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	ES	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
800059.403	FR	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.403	GB	Selective Heterocyclic	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	GR	Selective Heterocyclic	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403/1	Ж	Selective Heterocyclic	Granted	13103136.4	11/15/2010	1175652	4/26/2019	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	HK	Selective Heterocyclic	Abandoned	13103207.8	11/15/2010			CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403/2	HK	Selective Heterocyclic	Abandoned	16100725.4	11/15/2010			CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	H	Selective Heterocyclic	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	IL	Selective Heterocyclic	Granted	219692	11/15/2010	219692	9/30/2017	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	IN	Selective Heterocyclic	Abandoned	1430/KOLNP/2012	11/15/2010			CIS II
		Sphingosine I Phosphate Receptor Modulators						
800059.403	IT	Selective Heterocyclic	Granted	10830879.2	11/15/2010	2498609	4/18/2018	CIS II
		Sphingosine I Phosphate Receptor Modulators						
800059.403	JP	Selective Heterocyclic	Granted	2012-539064	11/15/2010	5922027	4/22/2016	CIS II
		Sphingosine 1 Phosphate Receptor Modulators						
800059.403	KR	Selective Heterocyclic	Granted	10-2012-7015220	11/15/2010	10-1771755	8/21/2017	CIS II
		Sphingosine 1 Phosphate						
		Receptor Modulators)					
800059.403	MX	Selective Heterocyclic	Granted	MX/a/2012/005559	11/15/2010	332934	9/3/2015	CIS II
		Sphingosine I Phosphate Receptor Modulators						

CIS II	8/28/2019	2706999	5/11/2012	12785231.7	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	CH	800059.404
CIS II			5/13/2011	61/486184	Expired	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	US	800059.404/P1
CIS II	11/1/2016	9481659	3/23/2015	14/117514	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	US	800059.404/PC
CIS II			11/15/2010	US2010/056759	Converted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	WO	800059.403
CIS II	12/2/2014	180754	11/15/2010	201203371-8	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	SG	800059.403
CIS II	4/18/2018	2498609	11/15/2010	10830879.2	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	SE	800059.403
CIS II	1/30/2017	025672	11/15/2010	201290329	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	RU	800059.403
CIS II	4/18/2018	2498609	11/15/2010	10830879.2	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	PT	800059.403
CIS II	6/20/2018	1-2012-500940	11/15/2010	1-2012-500940	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	РН	800059.403
CIS II	12/2/2014	599914	11/15/2010	599914	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	NZ	800059.403
CIS II	4/18/2018	2498609	11/15/2010	10830879.2	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	NL	800059.403
CIS II	4/15/2019	MY-169497-A	11/15/2010	PI-2012002100	Granted	Selective Heterocyclic Sphingosine 1 Phosphate Receptor Modulators	MY	800059.403
Assignee	Issue Date	Patent No.	Filing Date	Application No.	Status	Title	Country	Seed No.

Seed No.	Country	Title	Status	Application No.	Filing	Patent No.	Issue Date	Assignee
	•				D ate			Q
800059.405/C3	US	Novel GLP-1 Receptor	Abandoned	14/626719	2/19/2015			CIS II
		Stabilizers and						
		Modulators						
800059.405/C2	US	Novel GLP-1 Receptor Stabilizers and	Abandoned	14/329393	7/11/2014			CIS II
		Modulators						
800059.405/C4	SU	Novel GLP-1 Receptor	Abandoned	14/873563	10/2/2015			CIS II
		Stabilizers and						
		Modulators						
800059.405	EP	Novel GLP-1 Receptor	Abandoned	0.2025611	6/9/2011			CIS II
		Stabilizers and						
		Modulators						
800059.405	JP	Novel GLP-1 Receptor	Abandoned	2013-514378	6/9/2011			CIS II
		Modulators						
800059.405	OW	Novel GLP-1 Receptor	Converted	US2011/039873	6/9/2011			CIS II
		Stabilizers and						
		Modulators						
800059.406/PC	US	Novel GLP-1 Receptor	Granted	14/122176	2/28/2014	9278910	3/8/2016	CIS II
		Stabilizers and						
	112	Modulators	i					
800059.406/P1	US	Novel GLP-1 Receptor	Expired	61/491446	5/31/2011			CIS II
		Stabilizers and Modulators						
800059.406/P2	SU	Novel GLP-1 Receptor	Expired	61/535750	9/16/2011			CIS II
		Stabilizers and						
		Modulators						
800059.406/P3	US	Novel GLP-1 Receptor	Expired	61/569759	12/12/2011			CIS II
		Stabilizers and						
		Modulators						
800059.406/C1	SU	Novel GLP-1 Receptor	Abandoned	15/608740	5/30/2017			CIS II
		Stabilizers and						
		Modulators						
800059.406/D1	US	Novel GLP-1 Receptor	Granted	14/997364	1/15//2016	9700543	4/11/2017	CIS II
		Stabilizers and						
		Modulators						

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.406	PT	Novel GLP-1 Receptor	Granted	12793320.8	5/31/2012	2713722	3/15/2017	CIS II
		Stabilizers and						
		Modulators						
800059.406	SE	Novel GLP-1 Receptor Stabilizers and	Granted	12793320.8	5/31/2012	2713722	3/15/2017	CIS II
		Modulators						
800059.406	WO	Novel GLP-1 Receptor	Converted	US2012/040250	5/31/2012			CIS II
		Stabilizers and						
		Modulators						
800059.407/C2	US	Novel GLP-1 Receptor	Abandoned	15/050315	2/22/2016			CIS II
		Modulators						
800059.407/D1	US	GLP-1 Receptor	Granted	14/296907	6/5/2014	9187522	11/17/2015	CIS II
800059.407/P3	US	Novel GLP-1 Receptor	NP-Filed	61/734300	12/6/2012			CIS II
		Modulators						
800059.407/P1	US	Novel GLP-1 Receptor	NP-Filed	61/569754	12/12/2011			CIS II
		Stabilizers and						
800059.407/P2	US	Novel GLP-1 Receptor	NP-Filed	61/570789	12/14/2011			CIS II
		Stabilizers and						
		Modulators						
800059.407/C1	US	Novel GLP-1 Receptor	Abandoned	14/878660	10/8/2015			CIS II
		Modulators						
800059.407	US	GLP-1 Receptor	Granted	13/712624	12/12/2012	8778923	7/15/2014	CIS II
		Modulators						
800059.407	AU	Carboxylic Acid Derivatives Comprising	Granted	2012352349	12/12/2012	2012352349	11/30/2017	CIS II
		Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	BR	Novel GLP-1 Receptor	Pending	BR1120140139253	12/12/2012			CIS II
	2	Modulators			12/12/2012		11 15 / 15 15	272
800059.407	CA	Novel GLP-1 Receptor	Allowed	285/19/	12/12/2012	285/19/	11/26/2019	CIS II
		Modulators						

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.407	CN	Carboxylic Acid	Abandoned	201280060896.1	12/12/2012			CIS II
		Four Cycles Acting as						
		GLP-1 Receptor						
		of Diseases Such as						
800059.407	EP	Carboxylic Acid	Published	12806828.5	12/12/2012			CIS II
		Derivatives Comprising Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as Diabetes						
800059.407	НК	Novel GLP-1 Receptor Modulators	Abandoned	15102640.3	12/12/2012			CIS II
800059.407/1	HK	Carboxylic Acid	Published	15103363.6	12/12/2012			CIS II
		Derivatives Comprising						
		GLP-1 Receptor						
		Modulators for Therapy						
		Diabetes						
800059.407	Z	Carboxylic Acid Derivatives Comprising	Published	4969/DELNP/2014	12/12/2012			CIS II
		Four Cycles Acting as						
		GLP-1 Receptor Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	JP	Carboxylic Acid Derivatives Comprising	Granted	2014-546193	12/12/2012	6061949	12/22/2016	CIS II
		Four Cycles Acting as						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						

Seed No.	Country	Title	Status	Application No.	Filing	Patent No.	Issue Date	Assignee
	j	:			Date:			2
0000000007.407	NN	Carboxylic Acid	Audidolica	10-2014-7017345	12/12/2012			CISII
		Derivatives Comprising						
		Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	MX	Carboxylic Acid	Granted	MX/a/2014/006622	12/12/2012	365923	6/20/2019	CIS II
		Derivatives Comprising						
		Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	NZ	Carboxylic Acid	Granted	626122	12/12/2012	626122	1/31/2017	CIS II
		Four Cycles Acting as						
		GLP-1 Recentor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	RU	Carboxylic Acid	Granted	2014128522	12/12/2012	2634896	11/8/2017	CIS II
		Derivatives Comprising						
		Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						
800059.407	WO	Carboxylic Acid	Converted	US2012/069289	12/12/2012			CIS II
		Derivatives Comprising						
		Four Cycles Acting as						
		GLP-1 Receptor						
		Modulators for Therapy						
		of Diseases Such as						
		Diabetes						

Seed No.	Country	Title	Status	Application No.	Filing	Patent No.	Issue Date	Assignee
800059.408/C2	US	Novel GLP-1 Receptor Modulators	Granted	15/416758	1/26/2017	10259823	4/16/2019	CIS II
800059.408/P2	US	Novel GLP-1 Receptor Modulators	NP-Filed	61/981643	4/18/2014			CIS II
800059.408	SU	Novel GLP-1 Receptor Modulators	Granted	14/302260	6/11/2014	9260427	2/16/2016	CIS II
800059.408/P1	SN	Novel GLP-1 Receptor Modulators	NP-Filed	61/833737	6/11/2013			CIS II
800059.408/C1	SU	Novel GLP-1 Receptor Modulators	Granted	14/958513	12/3/2015	9598430	3/21/2017	CIS II
800059.408	AU	Novel GLP-1 Receptor Modulators	Granted	2014278183	6/11/2014	2014278183	1/17/2019	CIS II
800059.408	BR	Novel GLP-1 Receptor Modulators	Published	BR112015031040-0	6/11/2014			CIS II
800059.408	CA	Novel GLP-1 Receptor Modulators	Published	2913791	6/11/2014			CIS II
800059.408	CN	Novel GLP-1 Receptor Modulators	Granted	201480044849.7	6/11/2014	ZL201480044849.7	4/16/2019	CIS II
800059.408/1	CN	Novel GLP-1 Receptor Modulators	Published	201910207853.5	6/11/2014			CIS II
800059.408	EA	Novel GLP-1 Receptor Modulators	Granted	201592281	6/11/2014	030857	10/31/2018	CIS II
800059.408	EP	Novel GLP-1 Receptor Modulators	Published	14736554.8	6/11/2014			CIS II
800059.408/1	HK	Novel GLP-1 Receptor Modulators	Published	16110427.4	6/11/2014			CIS II
800059.408	HK	Novel GLP-1 Receptor Modulators	Published	16110429.2	6/11/2014			CIS II
800059.408/2	HK	Novel GLP-1 Receptor Modulators	Pending	19132974.7	6/11/2014			CIS II
800059.408	N	Novel GLP-1 Receptor Modulators	Published	11863/DELNP/2015	6/11/2014			CIS II
800059.408	JP	Novel GLP-1 Receptor Modulators	Granted	2016-519629	6/11/2014	6573604	8/23/2019	CIS II
800059.408	KR	Novel GLP-1 Receptor Modulators	Published	10-2016-7000708	6/11/2014			CIS II

CIS II	12/12/2017	9839664	9/13/2016	15/263637	Granted	Novel GLP-1 Receptor Modulators	US	800059.411/C1
CIS II	10/25/2016	9474755	7/24/2015	14/809020	Granted	GLP-1 Receptor Modulators	US	800059.411
CIS II			10/31/2014	US2014/063504	Converted	Selective Sphingosine 1 Phosphate Receptor Modulators and Combination Therapy Therewith	WO	800059.410
CIS II			10/31/2014	14799940.3	Abandoned	Selective Sphingosine 1 Phosphate Receptor Modulators and Combination Therapy Therewith	EP	800059.410
CIS II			1/27/2017	15/033311	Abandoned	Selective Sphingosine 1 Phosphate Receptor Modulators and Combination Therapy Therewith	US	800059.410/PC
CIS II			11/1/2013	61898971	NP-Filed	Selective Sphingosine 1 Phosphate Receptor Modulators and Combination Therapy Therewith	US	800059.410/P1
CIS II			6/19/2013	61/836950	Expired	Novel GLP-1 Receptor Modulators	US	800059.409/P1
						Modulators		
CIS II			6/11/2014	US2014/041997	Converted	Modulators Novel GLP-1 Receptor	WO	800059.408
CIS II	10/31/2018	030857	6/11/2014	201592281	Granted	Novel GLP-1 Receptor	RU	800059.408
CIS II			6/11/2014	715006	Pending	Novel GLP-1 Receptor Modulators	NZ	800059.408
CIS II	12/19/2019	370666	6/11/2014	MX/a/2015/016831	Granted	Novel GLP-1 Receptor Modulators	XM	800059.408
Assignee	Issue Date	Patent No.	Filing Date	Application No.	Status	Title	Country	Seed No.

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.411/C3	US	Novel GLP-1 Receptor Modulators	Abandoned	15/982909	5/17/2018			CIS II
800059.411/P2	US	Novel GLP-1 Receptor Modulators	NP-Filed	62/090040	12/10/2014			CIS II
800059.411/P3	US	Novel GLP-1 Receptor Modulators	NP-Filed	62/161650	5/14/2015			CIS II
800059.411/P1	SU	Novel GLP-1 Receptor Modulators	NP-Filed	62/028962	7/25/2014			CIS II
800059.411/C6	SU	Novel GLP-1 Receptor Modulators	Pending	16/827515	3/23/2020			CIS II
800059.411/C2	US	Novel GLP-1 Receptor Modulators	Abandoned	15/804762	11/6/2017			CIS II
800059.411/C5	US	Novel GLP-1 Receptor Modulators	Pending	16/538505	8/12/2019			CIS II
800059.411/C4	US	Novel GLP-1 Receptor Modulators	Abandoned	16/218278	12/12/2018			CIS II
800059.411	AU	Novel GLP-1 Receptor Modulators	Allowed	2015292356	7/24/2015			CIS II
800059.411	CA	Novel GLP-1 Receptor Modulators	Published	2955836	7/24/2015			CIS II
800059.411	СН	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II
800059.411	CN	Novel GLP-1 Receptor Modulators	Published	201580046095.3	7/24/2015			CIS II
800059.411	DE	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II
800059.411	EA	Novel GLP-1 Receptor Modulators	Granted	201790254	7/24/2015	032525	6/28/2019	CIS II
800059.411	EP	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II
800059.411	ES	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II
800059.411	FR	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II
800059.411	GB	Novel GLP-1 Receptor Modulators	Allowed	15745738.3	7/24/2015			CIS II

Seed No.	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Assignee
800059.411	IL	Novel GLP-1 Receptor Modulators	Pending	249896	7/24/2015			CIS II
800059.411	IT	Novel GLP-1 Receptor	Allowed	15745738.3	7/24/2015			CIS II
		Modulators						
800059.411	JP	Novel GLP-1 Receptor Modulators	Granted	2017-525324	7/24/2015	6556237	7/19/2019	CIS II
800059.411/1	JP	Novel GLP-1 Receptor	Published	2019-107866	7/24/2015			CIS II
		Modulators						
800059.411	KR	Novel GLP-1 Receptor Modulators	Published	10-2017-7003172	7/24/2015			CIS II
800059.411	XW	Novel GLP-1 Receptor	Pending	MX/a/2017/000972	7/24/2015			CIS II
		Modulators						
800059.411	NZ	Novel GLP-1 Receptor Modulators	Pending	728017	7/24/2015			CIS II
800059.411	RU	Novel GLP-1 Receptor	Granted	201790254	7/24/2015	032525	6/28/2019	CIS II
	2							
800059.411	SG	Novel GLP-1 Receptor Modulators	Granted	11201700364P	7/24/2015	11201700364P	3/10/2020	CIS II
800059.411	TH	Novel GLP-1 Receptor Modulators	Pending	1701000333	7/24/2015			CIS II
800059.411	OW	Novel GLP-1 Receptor	Converted	US2015/042114	7/24/2015			CIS II
800059.411	ZA	Novel GLP-1 Receptor	Granted	2017/00342	7/24/2015	2017/00342	12/19/2018	CIS II
		Modulators						
800059.412/C4	US	Novel GLP-1 Receptor	Pending	16/538553	8/12/2019			CIS II
		Modulators						
800059.412/C2	\overline{US}	Novel GLP-1 Receptor Modulators	Abandoned	16/008773	6/14/2018			CIS II
800059.412/C5	US	Novel GLP-1 Receptor	Pending	16/835046	3/30/2020			CIS II
		Modulators						
800059.412/C3	US	Novel GLP-1 Receptor	Abandoned	16/227510	12/20/2018			CIS II
	110	MIOUMAIOIS	11:1:1:1:1:1:1:1:1:1:1:1:1:1:1:1:1:1:1:1	(2) (2) (2)	10/10/2011			272
800059.412/P1	S	Novel GLP-1 Receptor Modulators	NP-Filed	62/090268	12/10/2014			CIS II
800059.412/P2	s_{Ω}	Novel GLP-1 Receptor	NP-Filed	62/161658	5/14/2015			CIS II
		Modulators						

CIS II			9/29/2016	62/401762	Expired	Compounds and Methods for Treating Lupus	US	800059.417/P1
CIS II			3/27/2019	16/337292	Published	Compounds and Methods for Treating Lupus	US	800059.417/PC
CIS II			9/29/2017	US2017/054298	Converted	Dimethylaminoethanol Salt of a GLP-1 Receptor Modulator	WO	800059.416
CIS II			9/29/2017	17781347.4	Published	Dimethylaminoethanol Salt of a GLP-1 Receptor Modulator	EP	800059.416
CIS II			9/30/2016	62/402565	Expired	Dimethylaminoethanol Salt of a GLP-1 Receptor Modulator	US	800059.416/P1
CIS II			6/17/2019	16/337298	Published	Dimethylaminoethanol Salt of a GLP-1 Receptor Modulator	US	800059.416/PC
CIS II			8/31/2017	US2017/049768	Converted	CXCR3 Receptor Agonists	WO	800059.415
CIS II			8/31/2017	MX/a/2019/002166	Pending	CXCR3 Receptor Agonists	MX	800059.415
CIS II			8/31/2017	2019-512307	Published	CXCR3 Receptor Agonists	JP	800059.415
CIS II			8/31/2017	17765033.0	Published	CXCR3 Receptor Agonists	EP	800059.415
CIS II			8/31/2017	3034108	Published	CXCR3 Receptor Agonists	CA	800059.415
CIS II			8/31/2017	2017318674	Pending	CXCR3 Receptor Agonists	AU	800059.415
CIS II			3/21/2019	16/335641	Allowed	CXCR3 Receptor Agonists	US	800059.415/PC
CIS II			9/2/2016	62/383202	Expired	CXCR3 Receptor Agonists	US	800059.415/P1
CIS II			3/29/2017	62/478496	NP-Filed	CXCR3 Receptor Agonists	US	800059.415/P2
Assignee	Issue Date	Patent No.	Filing Date	Application No.	Status	Title	Country	Seed No.

CIS II			3/27/2018	62/648878	Expired	Sphingosine 1 Phosphate Receptor Modulators	US	800059.424/P1
CIS II			3/29/2019	62/826790	Expired	Sphingosine 1 Phosphate Receptor Modulators	US	800059.424/P2
CIS II			3/2//2020	US2020/025138	Pending	Sphingosine I Phosphate Receptor Modulators	× C	800059.423
					:	Receptor Modulators		
CIS II			3/27/2018	62/648875	Expired	Sphingosine 1 Phosphate	US	800059.423/P1
CIS II			3/29/2019	62/826778	Expired	Sphingosine I Phosphate Receptor Modulators	S	800059.423/P2
					(Receptor Modulators		
CIS II			3/27/2020	US2020/025132	Pending	Sphingosine 1 Phosphate	WO	800059.422
CIS II			3/29/2019	62/826769	Expired	Sphingosine 1 Phosphate Receptor Modulators	S	800059.422/P2
						Receptor Modulators		
CIS II			3/27/2018	62/648858	Expired	Sphingosine 1 Phosphate	US	800059.422/P1
						Sclerosis		
						Relapsing Multiple		
						in Two Phase 3 Trials of		
						Volume at 1 and 2 Years		
					1	Preservation of Brain	č	
CIS II			8/11/2017	62/544467	Expired	Ozanimod Demonstrates	US	800059.421/P1
						Treated with Ozanimod		
						Multiple Sclerosis		
						Patients with Relapsing		
						Responder Phenotype in		
						Associated with a Super-		
						HDL Cholesterol are		
CIS II			5/10/2017	62/504206	Abandoned	Lower Baseline Levels of	US	800059.420/P1
						Neuroprotection		
						Receptor Agonists for		
CIS II			5/8/2018	US2018/031695	Converted	Sphingosine 1 Phosphate	WO	800059.419
0			D ate ")= 				
Assignee	Issue Date	Patent No.	Filing	Application No.	Status	Title	Country	Seed No.

Seed No.	Country	Title	Status	Application No.	Filing	Patent No.	Issue Date	Assignee
800059.425/P1	US	Sphingosine 1 Phosphate Receptor Modulators	Expired	62/648889	3/27/2018			CIS II
800059.425/P2	US	Sphingosine 1 Phosphate Receptor Modulators	Expired	62/826794	3/29/2019			CIS II
800059.425	WO	Sphingosine 1 Phosphate Recentor Modulators	Pending	US2020/025141	3/27/2020			CIS II
		Receptor Modulators						
800059.426/P2	SU	Sphingosine 1 Phosphate Receptor Modulators	Expired	62/826797	3/29/2019			CIS II
800059.426/P1	US	Sphingosine 1 Phosphate	Expired	62/648894	3/27/2018			CIS II
		Receptor Modulators						
800059.427/P2	US	Sphingosine 1 Phosphate	Expired	62/654152	4/6/2018			CIS II
		Receptor Modulator						
800059.427/P3	US	Sphingosine 1 Phosphate Receptor Modulator	Expired	62/662102	4/24/2018			CIS II
800059.427/P1	$^{ m US}$	Sphingosine 1 Phosphate	Expired	62/648837	4/27/2018			CIS II
		Tree-plot trioundation						
800059.429/P1	US	Sphingosine 1 Phosphate	Pending	62/839495	4/26/2019			CIS II
000050 100		Neceptor Information	-	1100000002110	2010000			CIC II
800059.429	WO	Sphingosine 1 Phosphate Receptor Modulator	Pending	US2020/025142	3/27/2020			CIS II
800059.430/P1	US	Super-Responder Phenotype for Treatment	Expired	62/690197	6/26/2018			CIS II
		with Sphingosine 1						
		Phosphate Receptor Agonist						
800059.431/P2	$\overline{\text{US}}$	Sphingosine 1 Phosphate Receptor Modulators	Pending	63/018327	4/30/2020			CIS II
800059.431/P1	US	Sphingosine I Phosphate	Pending	63/001073	3/27/2020			CIS II
	_					_	_	

RECORDED: 02/01/2021

Seed No.	Country Title	Title	Status	Application No.	Filing Date	Patent No.	Issue Date Assigned	Assignee
800059.432/P2 US	SU	Sphingosine 1 Phosphate	Pending	63/018333	4/30/2020			CIS II
			1					
800059.432/P1 US	SU	Sphingosine 1 Phosphate	Pending	63/001085	3/27/2020			CIS II
		Receptor Modulators						
800059.433/P2 US	US	Sphingosine 1 Phosphate	Pending	63/018347	4/30/2020			CIS II
		Receptor Modulators						
800059.433/P1 US	US	Sphingosine 1 Phosphate	Pending	63/001090	3/27/2020			CIS II
		Receptor Modulators						